### BNT162b2 immune responses

## Evaluation of the systemic and mucosal immune 1 response induced by COVID-19 and the BNT162b2 2 mRNA vaccine for SARS-CoV-2 3

Olaf Nickel<sup>4,1</sup>, Alexandra Rockstroh<sup>42,9</sup>, Johannes Wolf<sup>1,3</sup>, Susann Landgraf<sup>4</sup>, 4 Sven Kalbitz<sup>5</sup>, Nils Kellner<sup>3,5</sup>, Michael Borte<sup>3,4</sup>, Jasmin Fertey<sup>2,9</sup>, Christoph 5 Lübbert<sup>5,6,7</sup>, Sebastian Ulbert<sup>\$2,9</sup> and Stephan Borte<sup>\$,\* 1,3,8</sup> 6

- <sup>1</sup> Department of Laboratory Medicine, Hospital St. Georg, Leipzig, Germany;
- <sup>2</sup> Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany;
- <sup>3</sup> ImmunoDeficiencyCenter Leipzig, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency Diseases, Hospital St. Georg, Leipzig, Germany;
- <sup>4</sup> Hospital Vaccination Center, Hospital St. Georg, Leipzig, Germany;
- <sup>5</sup> Department of Infectious Diseases/Tropical Medicine, Nephrology and Rheumatology, Hospital St. Georg, Leipzig, Germany;
- <sup>6</sup> Interdisciplinary Center for Infectious Diseases, Leipzig University Hospital, Leipzig, Germany;
- <sup>7</sup> Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, Leipzig University Hospital, Leipzig, Germany;
- 8 Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
- <sup>7</sup> Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, Leipzig University Hospital, Leipzig, Germany;
- 7 8 9 10 11 12 13 14 15 16 17 18 19 20 12 22 23 <sup>8</sup> Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
- 9 Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Leipzig, Germany
- <sup>#</sup> authors contributed equally
- \*corresponding author
- 24

#### Keywords: COVID-19, SARS-CoV-2, vaccination, BNT162b2, neutralizing antibodies 25

26

#### **Manuscript main points:** 27

Immune responses towards BNT162b2 mRNA vaccination were studied prospectively and 28 revealed immunoprotective systemic effects for SARS-CoV-2 wildtype and the VOCs 29 B.1.617.2 and B.1.351. No relevant effect on mucosal immunity could be detected. Vaccine 30 responses indicated decreased efficacy towards B.1.617.2 and B.1.351 variant-of-concern in 31

- 32 neutralization assays.
- 33
- 34
- 35
- 36 **Corresponding author:**
- 37 Stephan Borte, MD, PhD
- 38 Head of the Department of Laboratory Medicine
- 39 Hospital St. Georg Leipzig
- 40 Delitzscher Strasse 141
- 41 D-04129 Leipzig
- 42 Germany
- 43 eNote: Stephan Rote of the second that has not been certified by peer review and should not be used to guide clinical practice.
- Phone: +49 (341) 909 3019 44

## BNT162b2 immune responses

## 45 **ABSTRACT**

# 46 Background

47 Currently used vaccines to protect from COVID-19 mostly focus on the receptor-binding
48 domain (RBD) of the viral spike protein, and induced neutralizing antibodies have shown to be
49 protective. However, functional relevance of vaccine-generated antibodies are poorly
50 understood on variants-of-concern (VOCs) and mucosal immunity.

# 51 Methods

We compared specific antibody production against the S1 subunit and the RBD of the spike protein, the whole virion of SARS-CoV-2, and monitored neutralizing antibodies in sera and saliva of 104 BNT162b2 vaccinees and 57 individuals with natural SARS-CoV-2 infection. Furthermore, we included a small cohort of 11 individuals which received a heterologous ChAdOx1-S/BNT162b2 prime-boost vaccination.

## 57 **Results**

Vaccinated individuals showed higher S1-IgG antibodies in comparison to COVID-19 patients, 58 followed by a significant decrease 3 months later. Neutralizing antibodies (nAbs) were poorly 59 60 correlated with initial S1-IgG levels, indicating that these might largely be non-neutralizing. In contrast, RBD IgGAM was strongly correlated to nAbs, suggesting that RBD-IgGAM is a 61 surrogate marker to estimate nAb concentrations after vaccination. The protective effect of 62 vaccine- and infection-induced nAbs was found reduced towards B.1.617.2 and B.1.351 VOCs. 63 NAb titers are significantly higher after third vaccination compared to second vaccination. In 64 contrast to COVID-19 patients, no relevant levels of RBD specific antibodies were detected in 65 saliva samples from vaccinees. 66

67

BNT162b2 immune responses

# 69 Conclusions

Our data demonstrate that BNT162b2 vaccinated individuals generate relevant neutralizing antibodies, which begin to decrease within three months after immunization and show lower neutralizing potential to VOCs as compared to the original Wuhan virus strain. A third booster vaccination provides a stronger nAb antibody response than the second vaccination. The systemic vaccine does not seem to elicit readily detectable mucosal immunity.

75

# 76 INTRODUCTION

Starting from the pandemic spread of the coronavirus disease in December 2019 (COVID-19), 77 global research efforts were made to identify effective vaccine candidates. Vaccines based on 78 79 vectors, inactivated viruses and mRNA were licensed, whereas the latter comprises a novel immunization technology. However, the kinetics of SARS-CoV-2 antibody production and the 80 persistence of humoral immunity following such a vaccination over time is of great interest for 81 national health services and the management of the pandemic. Recent studies suggested that 82 SARS-CoV-2 specific antibody production following vaccination with the BNT162b2 83 (BioNTech/Pfizer) mRNA vaccine is comparable to seroconversion following recovery from 84 COVID-19.[1] During SARS-CoV-2 infection, the median time to detect circulating antibodies 85 86 has been reported at 11 days after the onset of symptoms and this period will be affected by initial disease severity.[2] In patients with milder symptoms, some antibodies wane rapidly, 87 especially IgG against the nucleocapsid protein, whereas our group and others have shown that 88 antibodies to the spike protein and neutralizing antibodies remain detectable much longer.[3-5] 89 We performed a prospective study after the second BNT162b2 vaccination and assessed the 90 longevity of vaccine-induced antibodies for three and eight months in follow-up visits and 91 92 compared it with the humoral immune response after a third booster vaccination. Furthermore,

BNT162b2 immune responses

we analyzed effectiveness and kinetic of BNT162b2-induced nAbs against the variants of 93 94 concern B.1.351 (Beta) and B.1.617.2 (Delta) and. [6, 7] and the impact of the homologous BNT162b2 booster vaccination. Moreover, we also dissected the SARS-CoV-2 specific 95 antibody production in individuals that were vaccinated with a heterologous ChAdOx1-S vector 96 vaccine (AstraZeneca) and BNT162b2 mRNA vaccine (BioNTech/Pfizer) prime-boost regime. 97 In addition to systemic immunity, mucosal immune responses are considered to be critically 98 important in reducing SARS-CoV-2 spread. By mediation of the mucosa-associated lymphoid 99 tissue (MALT), a strong suppression of SARS-CoV-2 transmission can be achieved due to the 100 blockage of viral entry in mucosal cells of the oral cavity and pharynx. In saliva of recovered 101 102 COVID-19 patients, IgA antibodies are detectable in high concentrations.[8] Based on the route of application, it remains unclear if homologous mRNA or heterologous mRNA-vector 103 vaccination might elicit a partial mucosal immune response or does not provide any benefit in 104 105 generating a sterile mucosal immunity.

BNT162b2 immune responses

#### **PATIENTS AND METHODS** 107

#### Study design and human samples 108

- The study included two cohorts of vaccinated individuals that were followed prospectively and 109
- previously bio-banked samples from COVID-19 patients (Fig 1, Table 1). Study participants 110
- receiving homologous vaccination with the BNT162b2 mRNA vaccine (BNT/BNT, n=104, 111
- EMA fact sheet[9]) were recruited among healthcare employees at the Hospital St. Georg in 112
- Leipzig, Germany. Serum and saliva samples were collected on the day of first dose of 113
- vaccination (V1), on the day of the second dose vaccination (V2, median 21 days [IQR 21-22] 114
- after V1), and 14 to 28 days after the second dose vaccination (P1, median 42 days [IQR 42-115
- 43] after V1). We collected additional serum samples and dried blood spot samples (DBS) at 116
- time points P2 (25 individuals, 76 to 102 days after V2, median 102 days [IQR 99-109] after 117
- V1), P3 (41 individuals, [IQR 251-260] days after V2) and after booster vaccination (20 118
- 119 individuals, [IQR 14-16] days after P3).

- 123 Homologous BNT162b2 vaccinees received their second vaccination 3 weeks after the first dose, whereas 124 heterologous vaccinees received their second dose (BNT16b2) 10 weeks after the first vaccination with ChAdOx1-125 S
- 126 COVID-19 Patients: 35 days post symptom onset (PSO) (7-43)
- 127

(P1, median 91 days [IQR 90-92] after V1). 133

<sup>120</sup> Fig 1. Time points of blood sampling within the different cohorts in median days (min - max) 121 Vaccinees: V1 prior first vaccination, V2 21 days (21-27), P1 42 (35-49), P2 102 days (98-127) and P3 276 days 122 (252-286) after first vaccination. Boost samples were taken 309 (271-335) after first vaccination.

Another 11 study participants (63.6 % females, median age 31 [IQR 26-37]) received a 128 heterologous ChAdOx1-S vector based prime (EMA fact sheet [10]) and BNT162b2 boost 129 vaccination (AZ/BNT). In accordance to the homologous BNT/BNT group, serum samples 130 were collected on the day of the first dose of ChAdOx1-S vaccination (V1), 21 days after V1 131 (V2, median 21 days [IQR 20-22] after V1), and 12 to 15 days after second dose vaccination 132

BNT162b2 immune responses

COVID-19 patients

57

43.9

51

(32-79)

Inclusion into the study was independent of a previous SARS-CoV-2 infection. The ethics
committee of the Saxonian medical chamber approved the study (registry number EK-allg37/10–1) and informed consent was obtained from all volunteers.

As reference, 57 PCR-confirmed COVID-19 patients were included, which were treated 137 between March 3 and November 11, 2020, at the Department of Infectious Diseases/Tropical 138 Medicine, Nephrology and Rheumatology of the Hospital St. Georg. Serum samples were 139 collected between 7 and 43 days (Median 35 days, IOR 20-44) after symptoms onset. COVID-140 141 19 patients were stratified into two groups according to the WHO clinical progression scale (World Health Organization 2020 ordinal scale for clinical improvement): (1) "mild", scale 142 values 2 or 3 and (2) "moderate/severe" with scale values 4 or 5. For 29 of 34 COVID-19 143 144 patients with moderate/severe progression, saliva was collected (Table 1).

	Homologous vaccinees (BNT)	Heterologous vaccinees (AZ/ BNT)
N	104	11
Females (%)	68.3*	63.6*
Median age	41	31*
(min-max)	(20-66)	(26-37)
Median days after first dose		

145 Table 1: Demographic characteristics of vaccinees and COVID-19 cases

 P21
 102 (98-127)

 P3
 276 (252-286)

 Boost
 309 (271-335)

 Median days after the onset of symptoms (min-max)
 35

21 (21-27)

42 (35-49)

21 (20-22)

91 (90-92)

(min-max)

V2

P1

Vaccination reaction (%):

medRxiv preprint doi: https://doi.org/10.1101/2022.01.29.22270066; this version posted January 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . BNT162b2 immune responses None 11.5 0 Local<sup>2</sup> 0 14.4 Systemic<sup>3</sup> 74.0 100 severity of disease<sup>4</sup> (%) 57.9 mild (scale 2-3) moderate/severe (scale 4-5) 42.1

<sup>1</sup> blood sampling was done for 25 of 104 volunteers <sup>2</sup>pain at the vaccination site. <sup>3</sup>includes fever, chills, 146 147 headache, fatigue, nausea, diarrhea, body aches, and nerve pain. <sup>4</sup>Clinical severity of COVID-19 patients was classified according to the WHO clinical progression: (2) ambulatory without limitation of 148 149 activity, (3) hospitalized without oxygen, (4) hospitalized on oxygen therapy by mask or nasal prongs, 150 (5) hospitalized receiving non-invasive ventilation or high-flow oxygen therapy. Mann-Whitney-U test was used to analyze differences in age and Fisher's exact test was applied to evaluate difference in 151 gender (\* p<0.05, \*\*p<0.01). d = days, IQR = inter quartile range, n.s.= not significant. AZ = 152 153 AstraZeneca (ChAdOx1-S), BNT = BioNTech/Pfizer (BNT162b2), V2 = three weeks after first vaccination, P1 = two weeks after second vaccination, P2 = three month after second vaccination 154

155

## 156 Commercial assays for the detection of antibodies against S1 and Nucleocapsid

157 All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-

158 QuantiVac-ELISA, S1 Quant IgG; cut-off ≥25.6 BAU/ml) and for IgA against SARS-CoV-2

159 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio  $\geq 0.8$ ). Samples above detection limit

160 for S1 Quant IgG were pre-diluted 1:10 and 1:50 in sample buffer. In addition, baseline sera

161 were screened for IgG antibodies against SARS-CoV-2 nucleocapsid (Virotech, Rüsselsheim,

162 Germany; cut-off  $\geq 11$  VE/ml).

163

# 164 In-house developed enzyme-linked immunosorbent assays

165 Detection of SARS-CoV-2 inactivated whole virion (IWV) IgG-antibodies and SARS-CoV-2

166 RBD polyvalent IgGAM-antibodies was performed according to Rockstroh et al. 2021.[3]

167 Briefly, Nunc PolySorp plates were coated with 1.5 µl per well of inactivated SARS-CoV-2 wt

viral particles and 250 ng/well of RBD protein in 100 µl per well of carbonate coating buffer

169 (15 mM Na2CO3, 7 mM NaHCO3 pH 9.6) overnight at 4°C. RBD protein (AA residues 329-

BNT162b2 immune responses

538 of spike protein, strain Wuhan-Hu-1) was expressed in Drosophila S2 cells and purified 170 171 from cell culture supernatants with tandem immobilized metal affinity and size exclusion chromatography using the ÄKTA pure 25 l chromatography system (GeHealthcare). 172 SARS-CoV-2 viral particles were purified from infectious cell culture supernatants by 173 ultracentrifugation on a 30 % sucrose cushion in MSE buffer (10 mM MOPS, pH 6.8, 150 mM 174 NaCl, 1 mM EDTA) at 25,000 rpm for 3.5 h and 4°C. The pellet was resuspended in MSE 175 buffer and chemically inactivated with 0.1 % beta-propiolactone at 22°C. Sera (diluted 1:100) 176 were incubated for 1.5 h at room temperature and binding antibodies were detected using a 177 HRP-conjugated secondary goat anti human IgG antibody (Dianova, 1:20,000) or goat anti 178 179 human IgG+IgM+IgA H&L antibody (Abcam, 1:10,000) for 1 h at room temperature. TMB substrate (Biozol) was added after a final wash step and incubated for 25 minutes before the 180 reaction was stopped with 1 M H2SO4. Absorbance was detected at 450 nm with 520 nm as 181 182 reference in a microplate reader (Tecan). The cut-off values were determined for each antigen individually and were validated using 100 pre-pandemic serum samples. All measurements 183 were performed at least in duplicates. 184

185

#### **SARS-CoV-2** viral stocks 186

SARS-CoV-2 wildtype virus (wt) (isolate BetaCoV/Germany/BavPat1/2020, obtained from the 187 European Virus Archive Global, EVAg)[11], SARS-CoV-2 B.1.1.7 (isolate MUC1-IMB1-CB, 188 kindly provided by Klaus Überla from the Institute of Clinical and Molecular Virology, 189 University of Erlangen-Nürnberg) and SARS-CoV-2 B.1.351 (SARS-CoV-190 2/human/Germany/LE-B14HXA2/2021 kindly provided by Corinna Pietsch from the Institute 191 of Virology, University Hospital Leipzig) were propagated in VeroE6 cells. Cells were grown 192 to a confluence of approx. 80 - 90 % and were infected at a MOI of 0.001 in Dulbecco's 193 modified Eagle's medium (DMEM), supplemented with 2 % FCS and 1 % Pen/Strep. They 194

BNT162b2 immune responses

were incubated for 48 h at 37°C with 5 %  $CO_2$  until cytopathic effect (CPE) was visible. Virus containing supernatants were centrifuged at 4000 g for 10 min at 4°C and then stored at -80°C until use. Viral titers were determined using a focus-forming assay. All viral stocks were sequenced to verify their spike protein sequences and expected mutation sites.

199

## 200 SARS-CoV-2 neutralization assay

201 Focus reduction neutralization assays (FRNT) were performed according to Rockstroh et. al. 2021.[3] Briefly, heat-inactivated human serum samples were serially diluted in DMEM 202 203 without FCS from 1:2.5 to 1:5120 and incubated with 50-150 focus forming units of SARS-CoV-2 wt, B.1.1.7 or B.1.351 for 1 h at 37°C before addition to confluent Vero E6 monolayers 204 in 96-well plates. After an incubation of 1 h at 37°C, supernatant was removed, cells were 205 washed with PBS, overlaid with 1 % Methyl cellulose in DMEM with 2 % FCS and incubated 206 for 24-26 h at 37°C in 5 % CO2. Cells were fixed with 4% paraformaldehyde in PBS, 207 permeabilized and blocked with Perm-Wash buffer (0.1% saponin, 0.1% BSA in PBS). SARS-208 CoV-2 focus forming units were stained using a monoclonal rabbit anti-S1 antibody (CR3022. 209 abcam, 1:1,000) and a secondary goat anti-rabbit IgG HRP-conjugated antibody (Dianova, 210 1:1,000). After the addition of TrueBlue substrate (Seracare), spots were counted with an 211 ELISpot reader (AID Diagnostika). FRNT<sub>90</sub> titers were determined as the reciprocal of the last 212 dilution providing a minimum of 90 % neutralization of focus forming units in comparison to 213 the virus control without serum. A positivity cut-off of  $FRNT_{90} \ge 5$  was determined with 214 negative reference sera, data not shown. 215

216

217

medRxiv preprint doi: https://doi.org/10.1101/2022.01.29.22270066; this version posted January 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

BNT162b2 immune responses

## 219 Collection and detection of SARS-CoV-2 specific IgA in saliva

Saliva was collected using the Oracol Saliva Collection System (Oracol, Worcester, U.K.) 220 according to the manufacturer's specification. Aliquots were stored at -80°C in Protein Low-221 222 Bind microtubes (Eppendorf, Hamburg, Germany) until further use. Samples were centrifuged at 10,000 g for 5 min and the supernatant was collected. 25 µl of saliva was mixed with equal 223 amounts of LEGENDplex assay buffer and S1- or RBD-coated beads in a 5 ml polypropylene 224 225 FACS tube, sealed and incubated overnight at 7°C in the dark. Subsequently, the bead mixture was washed with 1 ml of LEGENDplex wash buffer at 250 g for 5 min and incubated with 25µl 226 of Streptavidin-conjugated anti-IgA detection antibody for 60 min on an orbital shaker at 800 227 228 rpm, followed by the addition of 25 µl of Streptavidin-PE conjugate for another 30 min (all from BioLegend, SanDiego, CA, U.S.). After another wash step, beads were resuspended in 229 500 µl of BD sheath fluid and analyzed using a BD FACS Lyric flow cytometer (BD 230 Biosciences, San Jose, CA, U.S.) with PMT voltage settings adapted to discriminate beads 231 specific for Spike S1- and Spike RBD-specific IgA antibodies. Binding of IgA antibodies was 232 233 evaluated as median fluorescence signals on detected beads.

234

# 235 Study design and human samples

For comparison of surrogate neutralizing antibody concentrations to SARS-CoV-2 in dried blood spot samples DBS, we included samples of 63 COVID-19 patients (53.9% female, median age 61 years, IQR 48-72) collected between 60 and 319 days (Median 177 days, IQR 146-258) after disease onset.

240

241

BNT162b2 immune responses

#### Validation of a dried blood spot based surrogate assay for SARS-CoV-2 nAbs 243

Given the superior value and importance of a correlate of serological neutralizing activity in 244 SARS-CoV-2 vaccinated individuals and COVID-19 patients, as well as to monitor seasonal 245 246 booster vaccinations, we intended to develop and validate a simple diagnostic platform using DBS. This ACE-2 competitive-binding assay uses non-purified serum eluates from DBS and is 247 scalable in a 96-well format for automated analysis on a suitable reader system capable of 248 detecting fluorophore-conjugated microbeads. 249

With this approach, we could verify neutralizing surrogates both in mild and severe COVID-250 19 courses, as well as in BNT162b2-vaccinated individuals, with the latter two showing 251 comparable levels as previously shown in the assessment of neutralizing antibodies using our 252 focus reduction neutralization assay (FRNT) with serum samples. Therefore, we compared 253 254 FRNT-suggested nAb titers in matched serum samples with calculated concentrations of neutralizing surrogate antibodies in DBS and found a high degree of correlation (S3). 255

256

### Detection of surrogate neutralizing antibodies to SARS-CoV-2 in saliva and dried blood 257 spot samples 258

Dried blood spot samples (DBS) were generated by applying peripheral venous blood on a GE 259 Healthcare / Whatman 903 filter paper (Little Chalfont, U.K.) allowed to dry at room 260 261 temperature for at least 4 hours. DBS were stored at 7°C until further use. 2 x 3.2 mm dots were generated using a PerkinElmer Wallac punching device and were sorted into 96-well 0.45 µM 262 PVDF plates (Merck Millipore, Billerica, MA, U.S.) with plate outlets sealed with a foil. 70 µl 263 264 of LEGENDplex assay buffer was applied and plates were sealed on top, centrifuged at 1000 g for 2 min and stored at 7°C overnight. The outlet foil then was removed and the DBS suspension 265 was drained from the plates by centrifugation at 1000 g for 5 min into a 96-well Protein 266

BNT162b2 immune responses

LowBind plate (Eppendorf, Hamburg, Germany). Saliva samples were collected, stored and 267 268 prepared as depicted above. 50 µl of DBS suspension or saliva was combined in a 5 ml polypropylene FACS tube together with 25 µl of SARS-CoV-2 neutralizing antibodies and 25 269 µl of SARS-CoV-2 neutralizing assay beads B3 (all from BioLegend, SanDiego, CA, U.S.) and 270 kept on an orbital shaker for 120 min at 800 rpm. Subsequently, the bead mixture was incubated 271 with 25 µl of Streptavidin-PE conjugate for another 30 min and finally washed with 1 ml of 272 273 LEGENDplex wash buffer at 250 g for 5 min. Beads were resuspended in 500 µl of BD sheath fluid and analyzed using a BD FACS Lyric flow cytometer with PMT voltage settings adapted 274 to detect beads specific for the ACE2 neutralization target. Binding of neutralizing antibodies 275 276 inversely correlates with the median fluorescence signal detected on beads.

277

#### 278 Statistical analysis

SPSS version 21 (IBM, Armonk, NY, USA) and GraphPad PRISM version 6 (GraphPad 279 Software, San Diego, CA, USA) were used for statistical calculations and generation of figures. 280 Statistical tests were calculated as paired or unpaired one-way ANOVA with Holm-Sidak's 281 multiple comparison test for the analysis of follow-up samples or vaccine and infection induced 282 283 antibodies, respectively. Fisher's exact test was applied for comparison of categorical variables.

284

#### RESULTS 285

#### Serological characterization of BNT162b2 vaccinees and COVID-19 patients 286

Among 104 individuals receiving a homologous BNT162b2 vaccination we analyzed S1, RBD, 287 inactivated whole virion (IWV) and neutralizing antibodies and drew comparisons to 57 288 289 COVID-19 patients with mild and severe courses serving as reference group (Table 1, Fig 2 A-

BNT162b2 immune responses

E).[3] SARS-CoV-2 neutralizing as well as S1, RBD and IWV binding antibodies were 290 detectable in most individuals three weeks after the first vaccination. Two weeks after the 291 second dose, nAb titers and binding antibodies to all tested antigens were significantly 292 increased. At this stage, nAb titers (Median FRNT<sub>90</sub> = 320) as well as IWV IgG antibody signals 293 were comparable to those induced by natural mild COVID-19 but did not reach the high levels 294 of patients having severe COVID-19 courses (4- and 1.3- fold decrease for nAb and IWV IgG 295 respectively) (Fig 2 A and E). In contrast, RBD IgGAM and S1 IgA antibody levels 296 corresponded to those induced after severe COVID-19 and were even significantly exceeded 297 by vaccine-induced S1 IgG antibodies (3.5 fold increase). For some individuals, IgG antibodies 298 against the inactivated whole virion of SARS-CoV-2 (IWV) were detected even before the first 299 300 vaccination.

301 Fig 2. BNT162b2 vaccination induced antibodies in comparison to SARS-CoV-2 infection induced antibodies 302 The presented data shows antibody ratios before first (V1), 3 weeks after first (V2), and 2 weeks after second 303 vaccination (P1), as well as antibodies in sera of patients after mild and severe COVID-19 course. (A) Reciprocal 304 titers of SARS-CoV-2 neutralizing antibodies (nAb) were measured in focus reduction neutralization assay with 305 90 % inhibition (FRNT<sub>90</sub>). (B) RBD IgGAM signals determined as sample/cut-off ratios (C) S1 quant IgG 306 antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1-IgA and 307 inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios

308 The horizontal dotted lines represent positivity cut-offs. Statistical analysis was performed with ordinary 1-way 309 ANOVA, Holm-Sidak's multiple comparison test \* = p < 0.05, \*\* = p < 0.01, \*\*\* = p < 0.001, \*\*\*\* = p < 0.001, ns 310 = not significant

- 311 x-marked data points represent vaccinees with a previous SARS-CoV-2 infection
- 312

The correlation between BNT162b2-induced S1 IgG, RBD IgGAM antibody signals and nAb 313 titers using Spearman's rank coefficient is presented in S1 Fig. Herein, S1 IgG and RBD 314 315 IgGAM antibodies indicated the strongest correlation to SARS-CoV-2 nAbs (r=0.93) (Fig 3 A-B), whereas IWV and S1-IgA correlation coefficients ranged between r=0.722 and 0.817 (S1 316

317 Fig C-D).

Fig 3 Ratios between SARS-CoV-2 neutralizing antibody titers and (A, C, D) RBD IgGAM, S1 IgA, IWV in 318 319 sample/calibrator ratios and (B) S1 quant IgG in BAU/ml. Sera of vaccinees two weeks after second vaccination 320 (P1) were compared with sera of COVID-19 patients with mild and severe courses according to WHO score (2-3 321 mild and 4-5 severe). Statistical analysis was performed with an ordinary 1-way ANOVA, Holm-Sidak's multiple comparison test \* = p < 0.05, \*\* = p < 0.01, \*\*\* = p < 0.001, \*\*\*\* = p < 0.0001, ns = not significant. 322

BNT162b2 immune responses

323

The heterologous AZ/BNT vaccination cohort showed similar nAb titers after the first dose in comparison to BNT162b2 vaccinees (S2 Fig). However, after the second vaccination significantly higher nAb titers (4 fold increase) were detected compared to the homologous mRNA vaccine group.

328

## 329 Comparison of binding and neutralizing SARS-CoV-2 antibodies

Ratios of binding to neutralizing antibodies were calculated to compare the proportion of 330 neutralizing antibodies induced by vaccination to convalescent individuals in each test (Fig 3). 331 Vaccinees presented a significantly lower proportion of neutralizing to S1 binding antibodies 332 in comparison to the COVID-19 group (10- fold and 5-fold lower for S1 IgG and S1 IgA 333 respectively). Similarly, this ratio was lower for RBD binding IgGAM antibodies compared to 334 patients after severe COVID-19 but was found comparable to the mild COVID-19 group. For 335 336 IWV-IgG the neutralizing proportion of binding antibodies was higher than in patients with mild COVID-19 courses but below the median of severe courses. 337

338

## 339 Long term kinetics of antibody titers

The kinetics of antibody abundance varied greatly, with a mean reduction of nAb by 3.3 fold at P2 and 9.7 fold at timepoint P3 compared to timepoint P1 two weeks after second vaccination. (Fig 4 A) RBD IgGAM ratios decreased 1.8 fold after three month and 4.0 fold after eight month (Fig 4 C). S1 antibody concentrations fall 5.7 fold at timepoint P2 and 36.6 fold at P3 (Fig 4 C). Smallest differences were observed in the IWV IgG antibody signals with a 1.1 fold mean reduction after three months and a 2.2 fold mean reduction after eight month (Fig 4 D).

348 90% (FRNT90). (B) RBD IgGAM signals were determined as sample/calibrator ratios (C) S1 IgG antibodies were 349 quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1 IgA and IWV (SARS-CoV-2 350 inactivated whole-virion) titers were determined as sample/calibrator ratios. (F) Fold reduction of SARS-CoV-2 351 neutralizing antibody titers, RBD IgGAM, S1 IgG, S1 IgA and IWV IgG antibody signals in follow-up vaccine 352 sera calculated as ratio of value on timepoint P1 to timepoint P3.

353

#### 354 Neutralizing effect of BNT162b2-induced antibodies on B.1.617.2 and B.1.351 VOCs

- Neutralizing antibody titers were decreased towards VOCs in almost all tested individuals and 355
- cohorts when compared with wildtype SARS-CoV-2 (Fig 5). A 5.1- and 11.5-fold mean titer 356
- 357 decrease was observed with the B.1.617.2 and B.1.351 variant, respectively. With 6.2-fold and
- 7.7-fold a similar nAb mean reduction was observed for both variants at P2. After eight month 358
- nAb titers for B.1.617.2 showed a 6.2 fold and for B.1.351 a 4.1 fold decrease. Compared to 359
- the homologous BNT/BNT vaccination group and Covid 19 convalescent group, the decrease 360
- of nAbs against VOCs was much smaller (2.5- to 3.5-fold decrease) in the heterologous 361
- 362 AZ/BNT vaccination cohort (S3 Fig).

363 Fig 5 BNT162b2- and infection induced reciprocal SARS-CoV-2 nAb titers on the wild-type strain wt-BavPat1 364 and the VOC strains B.1.617.2 and B.1.351 at timepoint P1 to timepoint P3. The dotted line indicates the limit-of-365 detection at a titer of 1:5. FRNT90: focus reduction neutralization titer at 90% virus inhibition; results plotted as 366 reciprocal values. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted above the 367 continuous lines \* = p < 0.05, \*\* = p < 0.01, \*\*\* = p < 0.001, \*\*\*\* = p < 0.0001, ns = not significant

368

#### Impact of booster vaccination to nAb titer level on wildtype, B.1.617.2 and B.1.351 strains 369

Two weeks after booster vaccination nAb titers are significantly higher compared to time point 370

- P1 after second vaccination. The median increase reaches from 6.1 fold for wildtype variant to 371
- 26.2 fold in B.1.351 (Fig 6 A). The comparison between time point P3 and boost shows median 372
- increase ranges between 76.3 fold and 138 fold (Fig 6 B). 373

<sup>374</sup> Fig 6 BNT162b2- induced reciprocal SARS-CoV-2 nAb titers on the wild-type strain wt-BavPat1 and the VOC 375 strains B.1.617.2 and B.1.351. (A) Nab titers were compared two weeks after second and third vaccination. (B) 376 Comparison of nAbs 8 month after second and two weeks after third vaccination. The dotted line indicates the

<sup>377</sup> limit-of-detection at a titer of 1:5. FRNT90: focus reduction neutralization titer at 90% virus inhibition; results

<sup>378</sup> plotted as reciprocal values. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted

above the continuous lines \* = p < 0.05, \*\* = p < 0.01, \*\*\* = p < 0.001, \*\*\*\* = p < 0.0001, ns = not significant 379

BNT162b2 immune responses

#### Validation of a dried blood spot based surrogate assay for SARS-CoV-2 nAbs 380

FRNT-suggested nAb titers in serum samples were highly comparable (r=0.664) (S4 Fig) to 381 concentration of neutralizing surrogate antibodies in DBS, as further outlined in the 382 383 Supplementary material.

384

#### 385 Detection of SARS-CoV-2 targeting antibodies in saliva samples

Saliva samples from vaccinees and COVID-19 patients with moderate or severe courses were 386 assessed for S1- and RBD-specific IgA antibodies using a sensitivity-trimmed bead-based flow-387 cytometric assay. Based on interquartile range calculation, no increase of IgA production at V2 388 or P1 was observed in the group of BNT162b2-vaccinated individuals. Similar results were 389 obtained for the AZ/BNT group (data not shown). In contrast, most COVID-19 patients had 390

detectable salivary IgA towards SARS-CoV-2 antigens after 15-30 days after the onset of 391

Fig 7. Salivary IgA specific to SARS-CoV-2 RBD in individuals prior first (V1), three weeks after first (V2) and 393 to weeks after second vaccination (P1) in comparison with COVID-19 patients. The dotted line indicates the 95% 394 395 interquartile range for vaccinees.

396

#### DISCUSSION 397

#### 398 Impact of vaccination against SARS-CoV-2 on antibody formation

Vaccination with mRNA- or vector-based vaccines represents a milestone in combating the 399

SARS-CoV-2 pandemic. To better understand their protective effects, we assessed the antibody 400

401 formation quantitatively and functionally after vaccination in comparison with natural SARS-

CoV-2 infections. Three weeks after the first vaccination with BNT162b2, in half of the subjects 402

- nAbs could be detected, which is of note with regard to recent studies linking early levels of 403
- nAbs with protection against SARS-CoV-2.[12] This suggests a presumably protective effect 404

symptoms (Fig 7). 392

BNT162b2 immune responses

already after the first vaccination with the BNT162b2 mRNA vaccine. Two weeks after the
second dose, all individuals developed high S1- and RBD-binding as well as SARS-CoV-2 nAb
titers. These results are in concordance with similar observations in studies on the mRNA-1273
vaccine.[13] Interestingly, an even stronger nAb production was observed in the group of
heterologous ChAdOx1-S/BNT162b2 vaccinated individuals. This indicates that a combination
of different SARS-CoV-2 vaccine classes leads to stronger humoral immune response which
may result in a better protective effect, as has also been shown by other studies. [14-17].

412

# 413 Long-term kinetics of SARS-CoV-2 antibody response after BNT162b2 vaccination

We have observed significant reduction of vaccine-induced antibody levels three months after 414 the second vaccination. Interestingly, S1 quant IgG and IgA antibodies decreased strongly, 415 whereas nAb levels and RBD-GAM dropped to a lesser extent.[18] Thus, the S1 quant IgG 416 ELISA does not seem to be an optimal diagnostic choice for determining longevity of humoral 417 immune responses after SARS-CoV-2 mRNA vaccination. Therefore, we propose the use of 418 RBD-IgGAM determination as a rapid and simple surrogate marker to estimate the levels of 419 nAbs after SARS-CoV-2 mRNA vaccination. One explanation for a better correlation between 420 RBD-IgGAM and nAbs could be a better RB-Domain presentation in the vaccine antigen. 421 Considering that a broader nAb production against the RBD region was observed in vaccinees 422 compared to COVID-19 patients.[19] Furthermore, as an alternative with potential for the easier 423 handling of study samples we introduced a new method to detect surrogate nAbs from dry blood 424 spot cards, and results from this assay highly correlated with the nAb data obtained in a classical 425 virus neutralization test. Of note, for any serological test addressing protective responses, 426 suitable cut-off levels reflecting the biological relevance would have to be determined within 427 future studies in larger patient cohorts. 428

BNT162b2 immune responses

As an observed decrease in SARS-CoV-2 antibody titers within a short diagnostic interval might lead to the demand of booster vaccination doses, it is important to also investigate the cellular and memory immune responses in order to provide a full picture of SARS-CoV-2 protection. Data from recovered COVID-19 patients implies the presence of memory B- and Tcells in almost all individuals up to eight months after SARS-CoV-2 infection.[5, 20]

434

# 435 Vaccination or SARS-CoV-2 infection induced nAbs against SARS-CoV-2 VOCs

The BNT162b2 vaccine was designed using the spike gene sequence of the original Wuhan 436 437 SARS-CoV-2 wildtype virus. During the pandemic spread of SARS-CoV-2, mutations created many viral variants and some of these mutations resulted in structural changes in the S protein, 438 thereby providing higher selection potential for increased transmission and pathogenicity of the 439 virus.[21, 22] In BNT/BNT vaccinees, our data revealed a 5.1-fold reduction in the 440 effectiveness of neutralizing antibodies against the B.1.617.2 VOC, thereby providing further 441 442 evidence for mRNA vaccination efficacy against this variant. For B.1.351, a significant 11.5fold reduction in neutralizing capacity was observed in vaccinees. These results agree with 443 recent studies.[23-25] 444

Data of individuals that were vaccinated with ChAdOx1-S and subsequently with BNT162b2 showed a lesser reduction of nAbs targeting VOCs. This leads to the conclusion that the combination of both vaccines results in more robust immune response regarding VOC infections. Of note, the group size for the heterologous vaccination is rather small compared with the homologous mRNA vaccinated one. Therefore, the data need to be re-confirmed with a larger cohort.

The booster immunization led to a significantly stronger production of SARS-CoV-2 specific nAbs compared to the threshold after second vaccination. Of note, the median increase was

BNT162b2 immune responses

even more pronounced for VOC variants. Eight months after second vaccination nAb titers
were reduced by a 10-fold factor. In some individuals, for B.1.617.2 and B.1.351 variants
antibody titers were even below the limit of detection of the FRNT assay.

The decline in the neutralizing serological effect in recovered patients is however more pronounced. Here, we observed a 21.5- to 34.7-fold decrease in nAb titers for patients with mild and a 34-to 75.3-fold reduction for patients with severe COVID-19 courses. In other studies, a 3.5-fold reduction against B.1.351 was reported in convalescent patients compared to the wildtype virus.[26] One third of the individuals with mild COVID-19 did not show any detectable nAbs against B.1.1.7 and B.1.351 at all.

462

# 463 BNT162b2 vaccination and mucosal immune response

Generation of an intermittent protective mucosal immunity is generally accepted in COVID-19 464 patients undergoing natural infection and constitutes a relevant component in the suppression 465 466 of pandemic SARS-CoV-2 dissemination. However, using available COVID-19 mRNA and vector-based vaccines, an immune response of mucosa associated lymphoid tissue (MALT) is 467 highly questionable. The protection of most systemic vaccinations against mucosal infection 468 469 solely relies on few circulating IgA and IgG antibodies which transudate from sera into the mucosa.[27] These results suggest that SARS-CoV-2 mRNA vaccination is not able to trigger 470 a detectable protective mucosal immune response. However, other groups recently detected S1 471 IgG antibodies in saliva of vaccinated healthcare workers, which might however be attributable 472 to undiscovered natural SARS-CoV-2 infections that occurred previously.[28] Additional 473 development of mucosal vaccines could be crucial to improve the suppression of the pandemic 474 spread of future potential SARS-CoV-2 VOCs. 475

BNT162b2 immune responses

#### Conclusions 477

478	BNT162b2 mRNA vaccination provided sustainable formation of SARS-CoV-2 neutralizing
479	antibodies in our studied cohort. To preserve detectable nAb titers after 6 months, a booster
480	vaccination should be considered, especially for the protection against variants of concern. A
481	heterologous vaccine regime involving ChAdOx1-S vector-based prime and BNT162b2 mRNA
482	vaccine boost even exceeded these titers of neutralizing antibodies and might thus feature
483	beneficial synergy. None of the studied vaccines induced detectable mucosal immune response.

484

#### 485 Author contributions and conflict-of-interest disclosure

486 O.N., J.W. and S.B. designed the study, performed assays, analyzed results and wrote the manuscript. A.R., J.F. 487 and S.U. performed assays, conducted analyses and wrote the manuscript. S.L., S.K., N.K., M.B. and C.L. recruited 488 probands/patients, critically discussed hypotheses and revised the manuscript. None of the authors declare 489 competing conflicts of interest.

490

#### 491 Funding and acknowledgements

492 This publication was supported by the Saxon State Ministry for Science, Culture and Tourism (grant SaxoCOV) 493 and the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European 494 Union's Horizon 2020 research and innovation program under grant agreement No 871029. Furthermore, the 495 ImmunoDeficiencyCenter Leipzig received founding from the Jeffrey Modell Foundation for Primary 496 immunodeficiency diseases.

497 The authors are indebted to the voluntary help of probands and patients to participate in this study. Furthermore, 498 we would like to particularly emphasize the efforts made by Ulrike Schmidt and Cathrin Crimmann, and all 499 participating doctors and nurses during the vaccination campaign. Moreover, we like to thank Ulrike Ehlert and 500 Steffen Jakob for their excellent technical assistance. We also thank Corinna Pietsch (Leipzig University Hospital) 501 and Klaus Überla (Erlangen-Nürnberg University) for supplying VOCs.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.29.22270066; this version posted January 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

BNT162b2 immune responses

## 503 Literature

5041.Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and505Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-50673.

507 2. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A 508 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, 509 and association with severity. Nat Commun. 2020;11(1):4704.

510 3. Rockstroh A, Wolf J, Fertey J, Kalbitz S, Schroth S, Lubbert C, et al. Correlation of humoral 511 immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and 512 symptomatic severity in a German COVID-19 cohort. Emerg Microbes Infect. 2021;10(1):774-81.

513 4. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 infection
514 induces long-lived bone marrow plasma cells in humans. Res Sq. 2020. Epub 2021/01/06. doi:
515 10.21203/rs.3.rs-132821/v1.

5. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-517 CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).

518 6. Makoni M. South Africa responds to new SARS-CoV-2 variant. Lancet. 2021;397(10271):267.

519 7. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are 520 emerging in India. Nat Med. 2021;27(7):1131-3.

- Alkharaan H, Bayati S, Hellstrom C, Aleman S, Olsson A, Lindahl K, et al. Persisting Salivary IgG
   Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population
   Surveys. J Infect Dis. 2021;224(3):407-14.
- 5249.BNT162b2Factsheet2021[18.08.2021].Availablefrom:525<a href="https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product

527 10. ChAdOx1-S Fact sheet: EMA; 2021 [18.08.2021]. Available from: 528 <u>https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-</u> 529 vaccine-astrazeneca-epar-product-information\_en.pdf.

11. Peter AS RE, Schulz SR, et al. A pair of non-competing neutralizing human monoclonal
antibodies protecting from disease in a SARS-CoV-2 infection model. bioRxiv. 2021. doi:
2021.04.16.440101.

12. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody
levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med.
2021. Epub 2021/05/19. doi: 10.1038/s41591-021-01377-8.

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA
Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920-31.

Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral
vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet. 2021. Epub 2021/08/10. doi: 10.1016/S0140-6736(21)01694-9.

542 15. Groß R ZM, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M,
543 Pöhlmann S, Beil A, Kroschel J, Jahrsdörfer B. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime544 boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv. 2021.
545 doi: <u>https://doi.org/10.1101/2021.05.30.21257971</u>.

- Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, et al. Heterologous primeboost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021. Epub 2021/08/02.
  doi: 10.1016/S1473-3099(21)00420-5.
- Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19 and
   mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide
   cohort study. Lancet Reg Health Eur. 2021;11:100249.

medRxiv preprint doi: https://doi.org/10.1101/2022.01.29.22270066; this version posted January 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

BNT162b2 immune responses

18. Van Elslande J, Gruwier L, Godderis L, Vermeersch P. Estimated half-life of SARS-CoV-2 antispike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers.
Clin Infect Dis. 2021. Epub 2021/03/12. doi: 10.1093/cid/ciab219.

19. Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, et al. The SARS-CoV-2
 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within
 the RBD. bioRxiv. 2021. Epub 2021/04/22. doi: 10.1101/2021.04.14.439844.

Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. Persistence of SARSCoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection.
Med (N Y). 2021;2(3):281-95 e4.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a
 SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438-43.

563 22. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes
564 in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell.
565 2020;182(4):812-27 e19.

56623.Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of567SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348-61 e6.

568 24. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, et al. SARS-CoV-2 variants 569 B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384-93 e12.

570 25. Jalkanen P KP, Häkkinen H, et al. COVID-19 mRNA vaccine induced antibody responses and 571 neutralizing antibodies against three SARS-CoV-2 variants. Research Square. 2021. doi: 572 10.21203/rs.3.rs-343388/v1

- 573 26. Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. Infection- and 574 vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host 575 Microbe. 2021;29(4):516-21 e3.
- 576 27. Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.
  577 Hum Vaccin Immunother. 2020;16(12):2921-31.

578 28. Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, letto G, lovino D, et al. Mucosal immune 579 response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2021;75:103788.











С

- V1 at day of 1<sup>st</sup> vaccination
- V2 at day of 2<sup>nd</sup> vaccination
- P1 post 2<sup>nd</sup> vaccination
- mild COVID WHO 2-3
- severe COVID WHO 4-5



















Ε



- P1 2 weeks post 2<sup>nd</sup> vaccination
- P2 3 months post 2<sup>nd</sup> vaccination
- A P3 8 months post 2<sup>nd</sup> vaccination



Α



В



- V1 at day of 1<sup>st</sup> vaccination
- V2 at day of 2<sup>nd</sup> vaccination
- P1 post 2<sup>rd</sup> vaccination
- COVID-19

Figure 7